Unibest

Pharmaceutical intermediates

Irinotecan Intermediates

1 pharmaceutical intermediate for Irinotecan. Indication: Colorectal cancer; Colorectal carcinoma; Non-Hodgkin lymphoma; Non-small cell lung cancer; Lung cancer; Ovarian cancer.

提交项目All intermediates

About Irinotecan

Originator
Yakult Honsha Co., Ltd
Indication
Colorectal cancer; Colorectal carcinoma; Non-Hodgkin lymphoma; Non-small cell lung cancer; Lung cancer; Ovarian cancer
Approved Date
06/14/1996

Available intermediates

1 intermediate currently listed for Irinotecan. Request specifications, documentation or a quotation for any item below.

Irinotecan intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
1-(2-Amino-5-hydroxyphenyl)propan-1-one35364-15-9//

Other programs under I

Ibrutinib/ Zanubrutinib IguratimodImatinibImeglimin hydrochlorideIndacaterol MaleateInfigratinibIpatacopan HydrochlorideIpragliflozin

Building toward Irinotecan?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →